Skip to main content

Table 1 Baseline characteristics of the guselkumab group (n = 12) and the adalimumab group (n = 13)

From: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

 

Guselkumab group (N=12)

Adalimumab group (N=13)

P value

Age

53.5 (46.0, 61.8)

55.0 (48.5, 58.0)

1.0000

Male/female

1/11

3/10

0.5930

Disease duration (months)

29.0 (6.3, 73.8)

18.0 (6.5, 324)

0.4459

Age at diagnosis

50.5 (41.5, 56.8)

45.0 (31.5, 55.5)

0.2530

Peripheral joint, n (%)

12 (100)

13 (100)

 

Sternoclavicular joint, n (%)

7/12 (58.3)

10/13 (76.9)

0.4110

Sacroiliac joint, n (%)

7/12 (58.3)

7/13 (53.9)

1.0000

Spine, n (%)

2/12 (16.7)

3/13 (23.1)

1.0000

Concomitant CS, n (%)

0 (0)

2 (16.7)

0.4857

History of csDMARDs

MTX 5, SASP 2

MTX 11, SASP 2, CyA 1

0.0730

History of TNFi, n (%)

4 (33.3)

2 (15.4)

0.1602

History of IL-17i, n (%)

1 (8.3)

0 (0)

0.4800

Weight (kg)

54.9 (48.3, 68.2)

56.1 (51.5, 72.8)

0.5496

BMI

21.7 (19.4, 27.7)

23.0 (20.5, 26.3)

0.4792

Smoking history, n (%)

8 (66.7)

9 (69.2)

1.0000

PPPASI

7.2 (1.7, 14.6)

3.0 (1.4, 18.6)

0.5137

Patient pain VAS (cm)

5.3 (3.0, 7.5)

4.5 (2.3, 6.6)

0.4138

Patient global VAS (cm)

5.3 (3.4, 7.5)

4.0 (3.5, 6.2)

0.3685

SJ66

1.5 (0, 3.0)

1.0 (0, 1.5)

0.3973

TJ68

4.0 (3.0, 7.3)

8.0 (3.5, 13.5)

0.1633

DAPSA

17.3 (10.3, 34.0)

19.7 (15.0, 26.8)

0.7223

HAQ

0.69 (0.28, 1.34)

0.75 (0.19, 1.50)

0.8911

EQ-5D

0.61 (0.54, 0.77)

0.61 (0.52, 0.73)

0.9738

CRP

0.13 (0.07, 0.65)

0.46 (0.05, 1.00)

0.8275

ESR

22.5 (9.0, 48.5)

19.0 (12.0, 25.0)

0.5853

  1. Data are shown by median (quartile) or n (%). p values were determined by Fisher’s exact test or the Wilcoxon rank sum test
  2. CS corticosteroid, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, TNFi tumor necrosis factor inhibitor, IL-17i interleukin 17 inhibitor, BMI body mass index, PPPASI Palmoplantar Pustulosis Area and Severity Index, VAS visual analog scale, SJ swollen joint, TJ tender Joint, DAPSA disease activity in psoriatic arthritis, HAQ Health Assessment Questionnaire, EQ-5D EuroQOL score with 5 dimensions, CRP C-reactive protein, ESR erythrocyte sedimentation rate
  3. *p<0.05: guselkumab group (n=12) vs adalimumab group (n=13)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us